The 23 references in paper S. Avdeev N., G. Baymkanova E., P. Zubairova A., N. Karchevskaya A., С. Авдеев Н., Г. Баймаканова Е., П. Зубаирова А., Н. Карчевская А. (2014) “Сравнение небулизированных бронхолитиков при обострении хронической обструктивной болезни легких // Comparison of nebulised bronchodilators in acute exacerbation of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2012:i:1:p:40-46

1
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2011. www.goldcopd.org
(check this in PDF content)
2
Stanford R.H., Shen Y., McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat. Respir. Med. 2006; 5: 343–349.
(check this in PDF content)
3
O'Donnell D.E., Parker C.M. COPD exacerbations: Pathophysiology. Thorax 2006; 61; 354–361.
(check this in PDF content)
4
Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.
(check this in PDF content)
5
Seemungal T.A.R., Donaldson G.C., Paul E.A. et al.Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 151: 1418–1422.
(check this in PDF content)
6
Miravitlles M., Murio C., Guerrero T. et al.Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449–1455.
(check this in PDF content)
7
Celli B.R., Barnes P.J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29: 1224–1238.
(check this in PDF content)
8
Smeeth L., Thomas S.L., Hall A.J. et al.Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 2004; 351: 2611–2618.
(check this in PDF content)
9
Seneff M.G., Wagner D.P., Wagner R.P. et al.Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. J.A.M.A. 1995; 274: 1852–1857.
(check this in PDF content)
10
Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.
(check this in PDF content)
11
Parker C.M., Voduc N., Aaron S.D. et al.Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur. Respir. J. 2005; 26: 420–428.
(check this in PDF content)
12
Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
(check this in PDF content)
13
Spencer S., Jones P.W.,GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589–593.
(check this in PDF content)
14
Gross N.J., Bankwala Z. Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease, comparison with a beta-adrenergic agent. Am. Rev. Respir. Dis. 1987; 136: 1091–1094.
(check this in PDF content)
15
Karpel J.P.The use of anticholinergic drugs in acute exacerbations of chronic obstructive pulmonary disease. In: Gross N.J., ed. Anticholinergic therapy in obstructive airways disease. London: Franklin Scientic Publications; 1993. 145–154.
(check this in PDF content)
16
Fernandez A., Muñoz J., Calle B. et al. Comparison of one versus two bronchodilators in ventilated COPD patients. Int. Care Med. 1994; 20: 199–202.
(check this in PDF content)
17
O'Driscoll B.R., Taylor R.J., Horsley M.G. et al.Nebulized salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; 2: 1418–1420.
(check this in PDF content)
18
Boe J., Dennis J.H., O'Driscoll B.R. et al.European Respiratory Society Guidelines on the use of nebulizers. Eur. Respir. J. 2001; 18: 228–242.
(check this in PDF content)
19
Авдеев С.Н., Нуралиева Г.С., Батын С.З. и др.Эффективность комбинированной терапии ингаляционными β2-агонистами и антихолинергическими препаратами при тяжелом обострении хронической обструктивной болезни легких: рандомизированное контролируемое исследование. Пульмонология 2007; 3: 56–65.
(check this in PDF content)
20
Bach P.B., Brown C., Gelfand S.E., McCrory D.C. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann. Intern. Med. 2001; 134: 600–620.
(check this in PDF content)
21
Авдеев С.Н. Небулайзерная терапия обструктивных заболеваний легких. Consilium Medicum 2011; 13 (3): 36–43.
(check this in PDF content)
22
Willaert W., Daenen M., Bornans P. et al. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur. Respir. J. 2002; 19: 928–935.
(check this in PDF content)
23
Guerin C., Chevre A., Dessirier P. et al.Inhaled fenoterolipratropium bromide in mechanically ventilated patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1036–1042. Информация об авторах
(check this in PDF content)